RP is an approved TPO mimetic for the treatment of idiopathic thrombocytopenic purpura (ITP) and promotes the activation of myeloproliferative leukaemia virus proto-oncogene (c-mpl) receptors and the production of platelets17. Here, TPO is linked to autoimmune thrombocytopenic purpura.